Beneficial effects of ethyl pyruvate in septic shock from peritonitis

Archives of Surgery

Volumn 142, Issue 2, 2007, Pages 166-171

  Su, Fuhong ^a   Wang, Zhen ^a   Cai, Ying ^a   Remmelink, Myriam ^a   Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; PYRUVIC ACID ETHYL ESTER; RINGER LACTATE SOLUTION; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL VENTILATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HYPOTENSION; NONHUMAN; OLIGURIA; ONCOTIC PRESSURE; PERITONITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; SEPTIC SHOCK; SHEEP; SURVIVAL TIME; TACHYCARDIA; UNIVERSITY HOSPITAL;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FLAVORING AGENTS; FOLLOW-UP STUDIES; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; PERITONITIS; PROSPECTIVE STUDIES; PYRUVATES; SHEEP; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 33847165372     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.142.2.166     Document Type: Article

References (38)

1. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34:344-353.
2. Fink MP. Ringer's ethyl pyruvate solution: a novel resuscitation fluid for the treatment of hemorrhagic shock and sepsis. J Trauma. 2003;54:S141-S143.
3. Venkataraman R, Kellum JA, Song M, Fink MP. Resuscitation with Ringer's ethyl pyruvate solution prolongs survival and modulates plasma cytokine and nitrite/nitrate concentrations in a rat model of lipopolysaccharide-induced shock. Shock. 2002;18:507-512.
4. Miyaji T, Hu X, Yuen PS, et al. Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int. 2003;64:1620-1631.
5. Ulloa L, Ochani M, Yang H, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A. 2002;99:12 351-12 356.
6. Sun Q, Dimopoulos G, Nguyen DN, et al. Low-dose vasopressin in the treatment of septic shock in sheep. Am J Respir Crit Care Med. 2003;168:481-486.
7. Su F, Nguyen ND, Creteur J, et al. Use of low tidal volume in septic shock may decrease severity of subsequent acute lung injury. Shock. 2004;22:145-150.
8. Uchiyama T, Delude RL, Fink MP. Dose-dependent effects of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion. Intensive Care Med. 2003;29:2050-2058.
9. Yang R, Gallo DJ, Baust JJ, et al. Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol. 2002;283:G212-G221.
10. Tawadrous ZS, Delude RL, Fink MP. Resuscitation from hemorrhagic shock with Ringer's ethyl pyruvate solution improves survival and ameliorates intestinal mucosal hyperpermeability in rats. Shock. 2002;17:473-477.
11. Sappington PL, Han X, Yang R, Delude RL, Fink MP. Ethyl pyruvate ameliorates intestinal epithelial barrier dysfunction in endotoxemic mice and immunostimulated caco-2 enterocytic monolayers. J Pharmacol Exp Ther. 2003;304:464-476.
12. Yang R, Uchiyama T, Watkins SK, Han X, Fink MP. Ethyl pyruvate reduces liver injury in a murine model of extrahepatic cholestasis. Shock. 2004;22:369-375.
13. Hauser B, Kick J, Asfar P, et al. Ethyl pyruvate improves systemic and hepatosplanchnic hemodynamics and prevents lipid peroxidation in a porcine model of resuscitated hyperdynamic endotoxemia. Crit Care Med. 2005;33:2034-2042.
14. Dubois EF. The estimation of the surface area of the body. In: Dubois EF, ed. Basal Metabolism in Health and Disease. Philadelphia, Pa: Lea & Febiger; 1936:125-144.
15. Shea LM, Beehler C, Schwartz M, Shenkar R, Tuder R, Abraham E. Hyperoxia activates NF-kappaB and increases TNF-alpha and IFN-gamma gene expression in mouse pulmonary lymphocytes. J Immunol. 1996;157:3902-3908.
16. Biagini GA, Park JH, Lloyd D, Edwards MR. The antioxidant potential of pyruvate in the amitochondriate diplomonads Giardia intestinalis and Hexamita inflata. Microbiology. 2001;147:3359-3365.
17. Bunton CA. Oxidation of α-diketons and α-keto-acids by hydrogen peroxide. Nature. 1949;163:444-446.
18. 2. Biochem J. 1988;252:913-915.
19. Dobsak P, Courderot-Masuyer C, Zeller M, et al. Antioxidative properties of pyruvate and protection of the ischemic rat heart during cardioplegia. J Cardiovasc Pharmacol. 1999;34:651-659.
20. Montgomery CM, Webb JL. Metabolic studies on heart mitochondria, II: the inhibitory action of parapyruvate on the tricarboxylic acid cycle. J Biol Chem. 1956;221:359-368.
21. Bunger R, Mallet RT, Hartman DA. Pyruvate-enhanced phosphorylation potential and inotropism in normoxic and postischemic isolated working heart: near-complete prevention of reperfusion contractile failure. Eur J Biochem. 1989;180:221-233.
22. Cicalese L, Lee K, Schraut W, Watkins S, Borle A, Stanko R. Pyruvate prevents ischemia-reperfusion mucosal injury of rat small intestine. Am J Surg. 1996;171:97-100.
23. Lee JY, Kim YH, Koh JY. Protection by pyruvate against transient forebrain ischemia in rats. J Neurosci. 2001;21:1-6.
24. Slovin PN, Huang CJ, Cade JR, et al. Sodium pyruvate is better than sodium chloride as a resuscitation solution in a rodent model of profound hemorrhagic shock. Resuscitation. 2001;50:109-115.
25. Mongan PD, Capacchione J, Fontana JL, West S, Bunger R. Pyruvate improves cerebral metabolism during hemorrhagic shock. Am J Physiol Heart Circ Physiol. 2001;281:H854-H864.
26. Yang R, Uchiyama T, Alber SM, et al. Ethyl pyruvate ameliorates distant organ injury in a murine model of acute necrotizing pancreatitis. Crit Care Med. 2004;32:1453-1459.
27. Song M, Kellum JA, Kaldas H, Fink MP. Evidence that glutathione depletion is a mechanism responsible for the anti-inflammatory effects of ethyl pyruvate in cultured lipopolysaccharide-stimulated RAW 264.7 cells. J Pharmacol Exp Ther. 2004;308:307-316.
28. Han Y, Englert JA, Yang R, Delude RL, Fink MP. Ethyl pyruvate inhibits nuclear factor-kappaB-dependent signaling by directly targeting p65. J Pharmacol Exp Ther. 2005;312:1097-1105.
29. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128:127-137.
30. Woo YJ, Taylor MD, Cohen JE, et al. Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia. J Thorac Cardiovasc Surg. 2004;127:1262-1269.
31. Leon H, Atkinson LL, Sawicka J, Strynadka K, Lopaschuk GD, Schulz R. Pyruvate prevents cardiac dysfunction and AMP-activated protein kinase activation by hydrogen peroxide in isolated rat hearts. Can J Physiol Pharmacol. 2004;82:409-416.
32. Kristo G, Yoshimura Y, Niu J, et al. The intermediary metabolite pyruvate attenuates stunning and reduces infarct size in in vivo porcine myocardium. Am J Physiol Heart Circ Physiol. 2004;286:H517-H524.
33. Hermann HP, Arp J, Pieske B, et al. Improved systolic and diastolic myocardial function with intracoronary pyruvate in patients with congestive heart failure. Eur J Heart Fail. 2004;6:213-218.
34. Olivencia-Yurvati AH, Blair JL, Baig M, Mallet RT. Pyruvate-enhanced cardioprotection during surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2003;17:715-720.
35. Mallet RT. Pyruvate: metabolic protector of cardiac performance. Proc Soc Exp Biol Med. 2000;223:136-148.
36. Lucas CE, Ledgerwood AM, Rachwal WJ, Grabow D, Saxe JM. Colloid oncotic pressure and body water dynamics in septic and injured patients. J Trauma. 1991;31:927-931.
37. Sims CA, Wattanasirichaigoon S, Menconi MJ, Ajami AM, Fink MP. Ringer's ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats. Crit Care Med. 2001;29:1513-1518.
38. Bates CM, Lin F. Future strategies in the treatment of acute renal failure: growth factors, stem cells, and other novel therapies. Curr Opin Pediatr. 2005;17:215-220.